44
Participants
Start Date
March 11, 2021
Primary Completion Date
February 5, 2024
Study Completion Date
February 5, 2024
CMP-001
Subjects will receive CMP-001 10 mg IT weekly for 7 doses after which CMP-001 will be administered every 3 weeks (Q3W).
Nivolumab
Nivolumab 360 mg IV is administered Q3W.
Columbia University Herbert Irving Comprehensive Cancer Center, New York
Memorial Sloan Kettering Cancer Center, New York
University of Pittsburgh Medical Center, Pittsburgh
Thomas Jefferson University, Philadelphia
Duke University Cancer Institute, Durham
Emory University Winship Cancer Institute, Atlanta
University Cancer & Blood Center, Athens
GenesisCare USA, Jacksonville
Orlando Health, Orlando
Cleveland Clinic Florida, Weston
University of Louisville Health Care, Louisville
The Ohio State University, Columbus
University of Iowa, Iowa City
Northwestern University, Chicago
Stephenson Cancer Center, Oklahoma City
Sammons Cancer Center, Dallas
University of Colorado- Denver, Denver
University of Utah- Huntsman Cancer Institute, Salt Lake City
Mayo Clinic, Phoenix
UCLA Hematology-Oncology, Los Angeles
City of Hope National Medical Center, Robert Kang, MD, Duarte
California Cancer Associates for Research & Excellence, Inc., San Marcos
Seattle Cancer Care Alliance, Seattle
Hartford Healthcare, Hartford
Massachusetts General Hospital, Boston
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Regeneron Pharmaceuticals
INDUSTRY